Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana 71130-3932.
Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana 71130-3932
J Neurosci. 2024 Apr 10;44(15):e1728232024. doi: 10.1523/JNEUROSCI.1728-23.2024.
DYT1 dystonia is a debilitating neurological movement disorder, and it represents the most frequent and severe form of hereditary primary dystonia. There is currently no cure for this disease due to its unclear pathogenesis. In our previous study utilizing patient-specific motor neurons (MNs), we identified distinct cellular deficits associated with the disease, including a deformed nucleus, disrupted neurodevelopment, and compromised nucleocytoplasmic transport (NCT) functions. However, the precise molecular mechanisms underlying these cellular impairments have remained elusive. In this study, we revealed the genome-wide changes in gene expression in DYT1 MNs through transcriptomic analysis. We found that those dysregulated genes are intricately involved in neurodevelopment and various biological processes. Interestingly, we identified that the expression level of RANBP17, a RAN-binding protein crucial for NCT regulation, exhibited a significant reduction in DYT1 MNs. By manipulating RANBP17 expression, we further demonstrated that RANBP17 plays an important role in facilitating the nuclear transport of both protein and transcript cargos in induced human neurons. Excitingly, the overexpression of RANBP17 emerged as a substantial mitigating factor, effectively restoring impaired NCT activity and rescuing neurodevelopmental deficits observed in DYT1 MNs. These findings shed light on the intricate molecular underpinnings of impaired NCT in DYT1 neurons and provide novel insights into the pathophysiology of DYT1 dystonia, potentially leading to the development of innovative treatment strategies.
DYT1 型肌张力障碍是一种使人衰弱的神经运动障碍疾病,也是最常见和最严重的遗传性原发性肌张力障碍。由于其发病机制不清楚,目前尚无治愈方法。在我们之前利用患者特异性运动神经元(MNs)的研究中,我们发现了与疾病相关的明显细胞缺陷,包括变形核、神经发育中断和核质转运(NCT)功能受损。然而,这些细胞损伤的确切分子机制仍不清楚。在这项研究中,我们通过转录组分析揭示了 DYT1 MNs 中基因表达的全基因组变化。我们发现,那些失调的基因与神经发育和各种生物过程密切相关。有趣的是,我们发现 RANBP17 的表达水平,一种对 NCT 调节至关重要的 RAN 结合蛋白,在 DYT1 MNs 中显著降低。通过操纵 RANBP17 的表达,我们进一步证明 RANBP17 在促进诱导人神经元中蛋白质和转录物货物的核运输中起着重要作用。令人兴奋的是,RANBP17 的过表达是一个重要的缓解因素,可有效恢复 DYT1 MNs 中受损的 NCT 活性并挽救神经发育缺陷。这些发现揭示了 NCT 在 DYT1 神经元中受损的复杂分子基础,并为 DYT1 肌张力障碍的病理生理学提供了新的见解,可能为开发创新的治疗策略提供了依据。